MX2019012171A - Tratamiento e inhibicion de enfermedades pulmonares inflamatorias en pacientes que tienen alelos de riesgo en los genes que codifican la il33 e il1rl1. - Google Patents
Tratamiento e inhibicion de enfermedades pulmonares inflamatorias en pacientes que tienen alelos de riesgo en los genes que codifican la il33 e il1rl1.Info
- Publication number
- MX2019012171A MX2019012171A MX2019012171A MX2019012171A MX2019012171A MX 2019012171 A MX2019012171 A MX 2019012171A MX 2019012171 A MX2019012171 A MX 2019012171A MX 2019012171 A MX2019012171 A MX 2019012171A MX 2019012171 A MX2019012171 A MX 2019012171A
- Authority
- MX
- Mexico
- Prior art keywords
- il1rl1
- inhibition
- patients
- treatment
- risk alleles
- Prior art date
Links
- 108700028369 Alleles Proteins 0.000 title abstract 2
- 208000019693 Lung disease Diseases 0.000 title 1
- 230000002757 inflammatory effect Effects 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 102100033500 Interleukin-33 Human genes 0.000 abstract 2
- 108010067003 Interleukin-33 Proteins 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 2
- 230000002327 eosinophilic effect Effects 0.000 abstract 2
- 208000030853 Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 102000045959 Interleukin-1 Receptor-Like 1 Human genes 0.000 abstract 1
- 108700003107 Interleukin-1 Receptor-Like 1 Proteins 0.000 abstract 1
- 208000000592 Nasal Polyps Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 108040006852 interleukin-4 receptor activity proteins Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762485077P | 2017-04-13 | 2017-04-13 | |
| PCT/US2018/023266 WO2018190990A1 (en) | 2017-04-13 | 2018-03-20 | Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019012171A true MX2019012171A (es) | 2019-11-25 |
Family
ID=61911717
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019012171A MX2019012171A (es) | 2017-04-13 | 2018-03-20 | Tratamiento e inhibicion de enfermedades pulmonares inflamatorias en pacientes que tienen alelos de riesgo en los genes que codifican la il33 e il1rl1. |
| MX2024002689A MX2024002689A (es) | 2017-04-13 | 2019-10-10 | Tratamiento e inhibicion de enfermedades pulmonares inflamatorias en pacientes que tienen alelos de riesgo en los genes que codifican la il33 e il1rl1. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024002689A MX2024002689A (es) | 2017-04-13 | 2019-10-10 | Tratamiento e inhibicion de enfermedades pulmonares inflamatorias en pacientes que tienen alelos de riesgo en los genes que codifican la il33 e il1rl1. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11708415B2 (enExample) |
| EP (3) | EP3957752B1 (enExample) |
| JP (3) | JP7321939B2 (enExample) |
| KR (2) | KR102751957B1 (enExample) |
| CN (1) | CN110431240A (enExample) |
| AU (3) | AU2018252974B2 (enExample) |
| CA (1) | CA3059350A1 (enExample) |
| IL (2) | IL269873B2 (enExample) |
| MX (2) | MX2019012171A (enExample) |
| SG (1) | SG11201909457XA (enExample) |
| WO (1) | WO2018190990A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018252974B2 (en) * | 2017-04-13 | 2024-10-17 | Regeneron Pharmaceuticals, Inc. | Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding IL33 and IL1RL1 |
| CN118994394A (zh) | 2017-06-12 | 2024-11-22 | 蓝鳍生物医药公司 | 抗-il1rap抗体和抗体药物缀合物 |
| JP7165618B2 (ja) * | 2019-04-23 | 2022-11-04 | ジェネシスヘルスケア株式会社 | アレルギー性鼻炎のリスクを判定する方法 |
| MA55807A (fr) * | 2019-05-01 | 2022-03-09 | Regeneron Pharma | Méthodes de traitement ou de prévention de l'asthme par administration d'un antagoniste d'il-33 |
| MX2022000649A (es) | 2019-07-16 | 2022-06-08 | Sanofi Biotechnology | Metodos para tratar o prevenir el asma mediante la administracion de un antagonista de il-4r. |
| MX2024005769A (es) * | 2021-11-11 | 2024-05-24 | Regeneron Pharma | Tratamiento de la enfermedad pulmonar basado en la estratificacion de puntuacion de riesgo poligenico para la interleucina 33 (il-33). |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6323334B1 (en) | 1999-09-24 | 2001-11-27 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules encoding a 103 gene product and uses therefor |
| EP2990420B1 (en) | 2000-05-26 | 2016-12-21 | Immunex Corporation | Use of interleukin-4 receptor antibodies and compositions thereof |
| WO2005047331A2 (en) | 2003-11-07 | 2005-05-26 | Immunex Corporation | Antibodies that bind interleukin-4 receptor |
| NZ549040A (en) | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
| CN101426518A (zh) * | 2006-01-11 | 2009-05-06 | 艾罗文斯公司 | 用于治疗人类和非-人类灵长类中哮喘的方法和组合物 |
| FR2900817B1 (fr) * | 2006-05-12 | 2008-12-19 | Gambro Lundia Ab | Bandage a usage medical pour un tube implante dans un patient, ainsi que le procede d'application de ce bandage sur la peau d'un patient |
| CN1896275B (zh) * | 2006-06-29 | 2010-04-07 | 四川大学华西医院 | 一种检测与慢性阻塞性肺部疾病相关的snp的pcr试剂盒 |
| US7560530B1 (en) | 2006-07-20 | 2009-07-14 | Schering Corporation | IL-33 receptor |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| WO2008054606A2 (en) | 2006-10-02 | 2008-05-08 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human il-4 receptor |
| US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
| US8367333B2 (en) * | 2008-12-12 | 2013-02-05 | Decode Genetics Ehf. | Genetic variants as markers for use in diagnosis, prognosis and treatment of eosinophilia, asthma, and myocardial infarction |
| WO2011031600A1 (en) | 2009-09-10 | 2011-03-17 | Schering Corporation | Use of il-33 antagonists to treat fibrotic disease |
| BR112013021473A2 (pt) | 2011-02-23 | 2020-08-04 | F. Hoffmann-La Roche Ag | anticorpos contra il33r humano e seus usos |
| US9090694B2 (en) | 2012-04-30 | 2015-07-28 | Janssen Biotech, Inc. | ST2L antibody antagonists |
| JO3623B1 (ar) | 2012-05-18 | 2020-08-27 | Amgen Inc | البروتينات المرتبطة بمولد المستضاد st2 |
| HUE064945T2 (hu) | 2012-08-21 | 2024-04-28 | Sanofi Biotechnology | Eljárások asztma kezelésére vagy megelõzésére IL-4R antagonista beadásával |
| CA2894219C (en) * | 2012-12-10 | 2020-08-11 | Vib Vzw | Novel interleukin-33 inhibitors |
| JO3532B1 (ar) * | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
| MX364591B (es) * | 2013-03-15 | 2019-05-02 | Regeneron Pharma | Antagonistas de il-33 y usos de estos. |
| TWI682781B (zh) | 2013-07-11 | 2020-01-21 | 美商再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| CA3190793A1 (en) | 2013-12-26 | 2015-07-02 | Mitsubishi Tanabe Pharma Corporation | Human anti-il-33 neutralizing monoclonal antibody |
| AU2015204674B2 (en) | 2014-01-10 | 2020-09-03 | Anaptysbio, Inc. | Antibodies directed against interleukin-33 (IL-33) |
| IL315136A (en) * | 2014-02-21 | 2024-10-01 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4rantagonist |
| NO2785538T3 (enExample) | 2014-05-07 | 2018-08-04 | ||
| CN107109494B (zh) | 2014-11-10 | 2023-10-27 | 豪夫迈·罗氏有限公司 | Il-33介导型疾病的治疗方法和诊断方法 |
| CA2960297A1 (en) | 2014-11-10 | 2016-05-19 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
| EP3218412A1 (en) * | 2014-11-14 | 2017-09-20 | Sanofi Biotechnology | Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist |
| CN104531689A (zh) * | 2014-12-12 | 2015-04-22 | 上海交通大学医学院附属新华医院 | 与哮喘相关的基因单核苷酸多态性位点、预测哮喘的试剂盒及其应用 |
| NZ736026A (en) | 2015-03-31 | 2023-02-24 | Medimmune Ltd | A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same |
| MX2018004170A (es) * | 2015-10-06 | 2018-06-06 | Regeneron Pharma | Biomarcadores relacionados con enfermedades mediadas por interleucina-33 (il-33) y usos de los mismos. |
| TWI857389B (zh) | 2016-12-01 | 2024-10-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
| AU2018252974B2 (en) * | 2017-04-13 | 2024-10-17 | Regeneron Pharmaceuticals, Inc. | Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding IL33 and IL1RL1 |
-
2018
- 2018-03-20 AU AU2018252974A patent/AU2018252974B2/en active Active
- 2018-03-20 KR KR1020237039438A patent/KR102751957B1/ko active Active
- 2018-03-20 WO PCT/US2018/023266 patent/WO2018190990A1/en not_active Ceased
- 2018-03-20 EP EP21162316.0A patent/EP3957752B1/en active Active
- 2018-03-20 EP EP18716446.2A patent/EP3610041A1/en not_active Withdrawn
- 2018-03-20 IL IL269873A patent/IL269873B2/en unknown
- 2018-03-20 IL IL314591A patent/IL314591A/en unknown
- 2018-03-20 JP JP2019555834A patent/JP7321939B2/ja active Active
- 2018-03-20 MX MX2019012171A patent/MX2019012171A/es unknown
- 2018-03-20 CA CA3059350A patent/CA3059350A1/en active Pending
- 2018-03-20 SG SG11201909457X patent/SG11201909457XA/en unknown
- 2018-03-20 EP EP25162154.6A patent/EP4549586A3/en active Pending
- 2018-03-20 KR KR1020197030870A patent/KR102605045B1/ko active Active
- 2018-03-20 CN CN201880018649.2A patent/CN110431240A/zh active Pending
-
2019
- 2019-10-10 MX MX2024002689A patent/MX2024002689A/es unknown
- 2019-10-11 US US16/599,709 patent/US11708415B2/en active Active
-
2023
- 2023-06-07 US US18/330,736 patent/US20230374145A1/en active Pending
- 2023-07-26 JP JP2023121229A patent/JP7557581B2/ja active Active
-
2024
- 2024-09-13 JP JP2024158740A patent/JP2024163308A/ja active Pending
- 2024-09-30 AU AU2024220212A patent/AU2024220212A1/en active Pending
- 2024-09-30 AU AU2024220214A patent/AU2024220214A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024002689A (es) | Tratamiento e inhibicion de enfermedades pulmonares inflamatorias en pacientes que tienen alelos de riesgo en los genes que codifican la il33 e il1rl1. | |
| PH12019501120A1 (en) | Methods of treating inflammatory conditions | |
| MX2020009780A (es) | Compuestos de inhibidor de autotaxina. | |
| WO2016077366A8 (en) | Therapeutic and diagnostic methods for il-33-mediated disorders | |
| NZ630805A (en) | Pharmaceutical combinations comprising a thionucleotide analog | |
| NZ710726A (en) | Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide | |
| PH12012502129A1 (en) | New combination therapy in treatment of oncological and fibrotic diseases | |
| WO2012093258A3 (en) | Irf5- related treatment and screening | |
| MX2015012322A (es) | Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes. | |
| PH12016501168B1 (en) | Bicalutamide analogs or (s)-bicalutamide as exocytosis activating compounds for use in the treatment of a lysosomal storage disorder or glycogenosis | |
| PH12016501371A1 (en) | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same | |
| MX2016006688A (es) | Inhibidores tetraciclicos de autotaxina. | |
| GB201205739D0 (en) | Treatment of acute inflammation in the respiratory tract | |
| MX2016016201A (es) | Particulas inhalables que comprenden una combinacion de un anticolinergico, un corticosteroide y un beta-adrenergico. | |
| HK1221190A1 (zh) | 炎症性眼科疾病的局部治疗 | |
| WO2015067710A3 (en) | Tyrp1, a natural mirna sponge, and its use in managing human melanoma aggressiveness | |
| HK1212902A1 (zh) | 诸如nps89636的钙/阳离子感应受体(casr)拮抗剂在治疗炎性肺病(哮喘或copd)中的应用 | |
| IL223065A0 (en) | New cathepsin s protease inhibitors, useful in the treatment of e.g. autoimmune disorders, allergy and chronic pain conditions | |
| PH12016502284A1 (en) | Cough medicine containing ambroxol hydrochloride | |
| HK40024981A (en) | Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1 | |
| WO2015051279A3 (en) | Cxcr4 up- and down-regulation for treatment of diseases or disorders | |
| Pociask et al. | C29 PROTECTORS OF THE LUNG: INNATE IMMUNE RESPONSES IN ACUTE LUNG INJURY: Il-22/Il-22 Binding Protein (il-22ra2) Balance Is Critical For The Resolution Of Influenza Induced Lung Pathology | |
| EA201991324A1 (ru) | Способы лечения воспалительных состояний | |
| PH12020500472A1 (en) | Autotaxin inhibitor compounds | |
| UA125130U (uk) | Спосіб лікування персистуючої бронхіальної астми у дітей із різними феногенотипами |